Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a poor prognosis. In this review, we focus on the role of the immune system in PDAC, especially the interactions between natural killer (NK) cells, cancer cells, and the tumor microenvironment (TME). These interactions are important for both tumor growth and resistance to treatment. Despite progress in treatment methods, PDAC remains difficult to manage, underscoring the need for new strategies to improve patient out-comes. NK cells are emerging as a potential therapeutic option, but their effectiveness is limited by a suppressive TME, which reduces NK cell activity and their ability to target tumors. Several mechanisms within the PDAC TME contribute to NK cell dysfunction. Key factors include diminished NK cell proliferation, impaired cytotoxicity, and reduced tumor infiltration. To address these challenges, we used a new concept known as the "Triple NK cell biomarker approach." This approach focuses on three critical factors: tumor characteristics, the TME, and NK cell suppression mechanisms. By identifying and targeting biomarkers associated with these components, the approach could help develop personalized strategies to enhance NK cell activity and improve PDAC treatment outcomes. While existing studies have highlighted the potential of NK cells in PDAC therapy, further research is essential to fully understand their role in treatment resistance.

This publication has 143 references indexed in Scilit: